Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Cytokinetics Inc a un objectif de cours consensus de $77.62, basé sur les évaluations des 22 analystes. Le plus élevé est de $120 attribué par HC Wainwright & Co. le septembre 29, 2025, et le plus bas est de $41 attribué par UBS le mai 2, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Barclays, B of A Securities et HC Wainwright & Co. le octobre 6, 2025, octobre 2, 2025 et septembre 29, 2025. Avec un objectif de cours moyen de $86 entre Barclays, B of A Securities et HC Wainwright & Co., il y a une variation implicite de 42.34% upside pour Cytokinetics Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Barclays
B of A Securities
HC Wainwright & Co.
B. Riley Securities
Evercore ISI Group
1calculé à partir des notes des analystes
Notes d'analystes pour Cytokinetics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/06/2025 | 35.72% | Barclays | $71 → $82 | Maintains | Overweight | |||
10/02/2025 | -7.32% | B of A Securities | $52 → $56 | Maintains | Neutral | |||
09/29/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
09/22/2025 | 32.41% | B. Riley Securities | $74 → $80 | Maintains | Buy | |||
09/22/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
09/03/2025 | 17.51% | Barclays | $53 → $71 | Maintains | Overweight | |||
09/03/2025 | 32.41% | Evercore ISI Group | $60 → $80 | Maintains | Outperform | |||
09/02/2025 | 39.03% | Citigroup | $77 → $84 | Maintains | Buy | |||
09/02/2025 | 58.89% | Stifel | $87 → $96 | Maintains | Buy | |||
09/02/2025 | 29.1% | JMP Securities | $78 → $78 | Reiterates | Market Outperform → Market Outperform | |||
09/02/2025 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
08/08/2025 | 27.44% | Citigroup | $80 → $77 | Maintains | Buy | |||
06/09/2025 | -12.28% | JP Morgan | $71 → $53 | Maintains | Overweight | |||
05/29/2025 | 39.03% | Mizuho | $103 → $84 | Maintains | Outperform | |||
05/14/2025 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
05/08/2025 | -12.28% | Barclays | $55 → $53 | Maintains | Overweight | |||
05/07/2025 | 32.41% | RBC Capital | $82 → $80 | Maintains | Outperform | |||
05/07/2025 | 32.41% | Citigroup | $86 → $80 | Maintains | Buy | |||
05/02/2025 | -32.14% | UBS | $47 → $41 | Maintains | Neutral | |||
05/02/2025 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
04/24/2025 | -8.97% | Barclays | → $55 | Initiates | → Overweight | |||
04/21/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
04/15/2025 | -10.63% | B of A Securities | $62 → $54 | Maintains | Neutral | |||
04/15/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
04/10/2025 | 29.1% | JMP Securities | $78 → $78 | Reiterates | Market Outperform → Market Outperform | |||
04/08/2025 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
04/04/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
04/03/2025 | 29.1% | Citizens Capital Markets | $78 → $78 | Reiterates | Market Outperform → Market Outperform | |||
02/28/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
02/13/2025 | 10.89% | Morgan Stanley | $70 → $67 | Upgrade | Equal-Weight → Overweight | |||
02/07/2025 | 42.34% | Citigroup | → $86 | Initiates | → Buy | |||
02/07/2025 | 29.1% | JMP Securities | $78 → $78 | Reiterates | Market Outperform → Market Outperform | |||
02/06/2025 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
01/22/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
01/22/2025 | 32.41% | Stifel | → $80 | Initiates | → Buy | |||
01/21/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
01/14/2025 | 29.1% | JMP Securities | $78 → $78 | Reiterates | Market Outperform → Market Outperform | |||
01/14/2025 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
01/10/2025 | — | HC Wainwright & Co. | — | Reiterates | Buy → Buy | |||
12/23/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
12/20/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
12/18/2024 | 35.72% | RBC Capital | $80 → $82 | Maintains | Outperform | |||
12/03/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
12/02/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
12/02/2024 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
11/21/2024 | 70.47% | Mizuho | $99 → $103 | Maintains | Outperform | |||
11/20/2024 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
11/19/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
11/18/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
11/11/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
11/08/2024 | 32.41% | RBC Capital | → $80 | Initiates | → Outperform | |||
11/07/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
10/18/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
10/17/2024 | 98.61% | HC Wainwright & Co. | $120 → $120 | Reiterates | Buy → Buy | |||
10/17/2024 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
10/09/2024 | 98.61% | HC Wainwright & Co. | $90 → $120 | Maintains | Buy | |||
09/30/2024 | 48.96% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
09/20/2024 | 48.96% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
09/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
09/09/2024 | 48.96% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
09/05/2024 | 17.51% | JP Morgan | $65 → $71 | Maintains | Overweight | |||
09/04/2024 | 29.1% | JMP Securities | $78 → $78 | Reiterates | Market Outperform → Market Outperform | |||
09/03/2024 | 48.96% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
09/03/2024 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
08/13/2024 | -0.7% | Goldman Sachs | $85 → $60 | Downgrade | Buy → Neutral | |||
08/12/2024 | 48.96% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
08/09/2024 | 19.17% | Needham | $72 → $72 | Reiterates | Buy → Buy | |||
06/24/2024 | 7.58% | JP Morgan | $77 → $65 | Maintains | Overweight | |||
06/17/2024 | 48.96% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
06/04/2024 | 52.27% | B. Riley Securities | $122 → $92 | Maintains | Buy | |||
05/31/2024 | 29.1% | JMP Securities | $78 → $78 | Reiterates | Market Outperform → Market Outperform | |||
05/29/2024 | 15.86% | Truist Securities | $86 → $70 | Maintains | Buy | |||
05/28/2024 | 29.1% | JMP Securities | $106 → $78 | Maintains | Market Outperform | |||
05/23/2024 | 48.96% | HC Wainwright & Co. | $94 → $90 | Maintains | Buy | |||
05/23/2024 | -0.7% | B of A Securities | $70 → $60 | Maintains | Neutral | |||
05/23/2024 | 57.23% | Barclays | $100 → $95 | Maintains | Overweight | |||
05/23/2024 | 15.86% | Raymond James | $92 → $70 | Maintains | Outperform | |||
05/23/2024 | 19.17% | Needham | $108 → $72 | Maintains | Buy | |||
05/14/2024 | 15.86% | B of A Securities | $75 → $70 | Maintains | Neutral | |||
05/14/2024 | 75.44% | JMP Securities | $106 → $106 | Reiterates | Market Outperform → Market Outperform | |||
05/14/2024 | 55.58% | HC Wainwright & Co. | $94 → $94 | Reiterates | Buy → Buy | |||
05/14/2024 | 78.75% | Needham | $108 → $108 | Reiterates | Buy → Buy | |||
05/09/2024 | 55.58% | HC Wainwright & Co. | $94 → $94 | Reiterates | Buy → Buy | |||
05/09/2024 | 78.75% | Needham | $108 → $108 | Reiterates | Buy → Buy | |||
05/09/2024 | 75.44% | JMP Securities | $110 → $106 | Maintains | Market Outperform | |||
05/09/2024 | 75.44% | Oppenheimer | $107 → $106 | Maintains | Outperform | |||
05/08/2024 | 55.58% | HC Wainwright & Co. | $94 → $94 | Reiterates | Buy → Buy | |||
04/09/2024 | 78.75% | Needham | → $108 | Reiterates | Buy → Buy | |||
04/08/2024 | 42.34% | Truist Securities | $86 → $86 | Reiterates | Buy → Buy | |||
03/07/2024 | 27.44% | JP Morgan | $78 → $77 | Maintains | Overweight | |||
03/06/2024 | 63.85% | Mizuho | $103 → $99 | Maintains | Buy | |||
03/04/2024 | 77.09% | Oppenheimer | → $107 | Reiterates | Outperform → Outperform | |||
02/28/2024 | 55.58% | HC Wainwright & Co. | $94 → $94 | Reiterates | Buy → Buy | |||
02/28/2024 | 78.75% | Needham | $108 → $108 | Reiterates | Buy → Buy | |||
01/24/2024 | 52.27% | UBS | $61 → $92 | Downgrade | Buy → Neutral | |||
01/22/2024 | 70.47% | Mizuho | $80 → $103 | Maintains | Buy | |||
01/08/2024 | 101.92% | B. Riley Securities | $66 → $122 | Maintains | Buy | |||
01/05/2024 | 48.96% | Morgan Stanley | $60 → $90 | Downgrade | Overweight → Equal-Weight | |||
12/28/2023 | 42.34% | Truist Securities | $60 → $86 | Maintains | Buy | |||
12/28/2023 | 52.27% | Raymond James | $63 → $92 | Maintains | Outperform |
FAQ
Quel est le cours indicatif de l'action Cytokinetics (CYTK) ?
Le dernier objectif de prix pour Cytokinetics (NASDAQ:CYTK) a été rapporté par Barclays le octobre 6, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $82.00 s'attendant à ce que CYTK se rise dans les 12 prochains mois (un possible changement de 35.63% upside). 55 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Cytokinetics (CYTK) ?
La dernière note d'analyste pour Cytokinetics (NASDAQ:CYTK) a été fournie par Barclays, et Cytokinetics maintenu leur note overweight.
Quand a eu lieu la dernière mise à niveau pour Cytokinetics (CYTK) ?
La dernière amélioration pour Cytokinetics Inc a eu lieu le février 13, 2025 lorsque Morgan Stanley a augmenté leur objectif de prix à $67. Morgan Stanley avait précédemment an equal-weight pour Cytokinetics Inc.
Quand a eu lieu la dernière dégradation pour Cytokinetics (CYTK) ?
La dernière réduction pour Cytokinetics Inc a eu lieu le août 13, 2024 lorsque Goldman Sachs a changé leur objectif de prix de $85 à $60 pour Cytokinetics Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Cytokinetics (CYTK) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Cytokinetics, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Cytokinetics a été déposée le octobre 6, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 6, 2026.
La note d'analyste pour Cytokinetics (CYTK) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Cytokinetics (CYTK) était un maintenu avec un objectif de prix de $71.00 à $82.00. Le prix actuel de Cytokinetics (CYTK) est de $60.46, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.